Loading...
XSHG
600587
Market cap1.07bUSD
Jul 10, Last price  
12.02CNY
1D
0.92%
1Q
-16.59%
Jan 2017
-52.13%
IPO
132.05%
Name

Shinva Medical Instrument Co Ltd

Chart & Performance

D1W1MN
XSHG:600587 chart
P/E
13.85
P/S
0.75
EPS
0.87
Div Yield, %
4.20%
Shrs. gr., 5y
2.89%
Rev. gr., 5y
1.25%
Revenues
9.74b
-2.84%
483,164,962528,908,872654,964,324885,836,6161,342,233,4082,106,132,0623,035,561,2254,193,764,3166,283,466,6697,554,444,2508,364,495,5309,983,246,17110,283,639,0278,766,761,0759,150,960,4109,482,198,7509,281,768,65610,011,868,42310,020,618,6249,736,089,608
Net income
526m
-23.90%
21,273,91822,433,86529,868,33841,286,79060,352,282107,257,530163,311,039231,680,204326,441,345280,833,88934,636,29865,528,72722,784,147861,314,745234,138,982556,493,791500,072,202653,997,278691,609,561526,335,669
CFO
701m
+55.44%
58,141,917049,285,184106,291,491124,164,572010,867,02522,355,70052,058,790110,434,996188,745,622947,089,785653,215,493630,910,0801,098,102,3941,402,538,527388,048,5661,030,114,479450,733,485700,636,920
Dividend
Oct 24, 20250.25 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Established in 1943 and headquartered in Zibo, China, Shinva Medical Instrument Co., Ltd. is a prominent provider of medical instruments and equipment within the People's Republic of China. The company's extensive product portfolio spans a wide array of specialized areas. These include comprehensive solutions for central sterile supply departments (CSSD), pharmaceutical manufacturing, radiotherapy, and digital operating rooms. They also cater to dental practices, medical environmental protection, and experimental animal care. Furthermore, their range encompasses in vitro diagnostic reagents and instruments, as well as biomedical materials and supplies. Beyond these, Shinva also manufactures pharmaceutical machinery and air purification systems.
URL
http://www.shinva.net
IPO date
Sep 27, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT